Medication info
Terazol Tablets (Terbinafine Hydrochloride)

Terazol Tablets (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Korea Pharma Co., Ltd.
Appearance
White round tablets
Packaging
30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 200401720 · Notified 2004.05.29 · Insurance code 653002390

Summary

Main use
Treatment of onychomycosis and dermatomycosis (e.g., tinea pedis, tinea corporis, and tinea capitis)
Who takes it
Adults · Children
Adult dose
1. Adults Administer terbinafine 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows: 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually administered for 6 weeks~3 months. For infections of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow nail growth. 3. Patients with renal impairment For patients with creatinine clearance below 50 mL/min, reduce the daily dose by 1/2.
Child dose
2. Children: Administer to children aged 2 years and older. Use is not recommended in children under 2 years of age because there is no experience with administration in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the appropriate prescribed period. 1) Body weight below 20 kg (under 5 years): Administer 62.5 mg once daily. As experience with administration is limited, decide whether to administer by weighing the benefits and risks of treatment. 2) Body weight 20~40 kg (5~12 years): Administer 125 mg once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Ingredients

Manufacturer
Korea Pharma Co., Ltd.

Efficacy & effects

Treatment of onychomycosis and dermatomycosis (e.g., tinea pedis, tinea corporis, and tinea capitis)

  • Dermatophyte infections
  • athlete's foot
  • tinea corporis
  • tinea cruris
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used for the treatment of dermatophyte infections of the skin such as athlete's foot, tinea corporis, tinea cruris, and onychomycosis in adults. It is also effectively used for tinea capitis in children. It helps improve symptoms by treating fungal infections of the skin and nails.

How to take

Adult dose

1. Adults Administer terbinafine 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows: 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually administered for 6 weeks~3 months. For infections of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow nail growth. 3. Patients with renal impairment For patients with creatinine clearance below 50 mL/min, reduce the daily dose by 1/2.

Child dose

2. Children: Administer to children aged 2 years and older. Use is not recommended in children under 2 years of age because there is no experience with administration in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the appropriate prescribed period. 1) Body weight below 20 kg (under 5 years): Administer 62.5 mg once daily. As experience with administration is limited, decide whether to administer by weighing the benefits and risks of treatment. 2) Body weight 20~40 kg (5~12 years): Administer 125 mg once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Precautions

This medication should preferably not be used in patients with chronic liver disease or active liver disease. Before taking this medication, liver function tests must be conducted, and liver function should be regularly monitored during treatment. If symptoms of liver dysfunction occur, the medication should be discontinued immediately and a physician consulted. This medication should not be administered to patients with certain blood disorders, severe renal failure, children under 2 years of age, or breastfeeding women. Additionally, patients with hypersensitivity to this medication should not take it. Caution is required when administering to the elderly or those with impaired kidney function, and care should be taken when dosing in underweight children. This medication can cause severe skin reactions; therefore, it should be stopped immediately if symptoms like rash or itching occur. Special attention should be given if musculoskeletal symptoms like myalgia or arthralgia emerge. If serious side effects such as dizziness or hypotension occur, discontinue the medication immediately and inform healthcare professionals. This medication may interact with other drugs; thus, inform healthcare providers of any concurrent medications being taken. Specifically, dosage adjustments may be necessary when used with drugs metabolized in the liver. Women who are pregnant or may become pregnant should carefully consider the risks and benefits of using this medication, and breastfeeding should be discontinued if this medication is taken. In case of overdose, symptoms such as headache, nausea, and dizziness can occur, and immediate medical attention should be sought. This medication should be kept out of reach of children and stored at room temperature away from direct sunlight. Dizziness may occur when driving or operating machinery, so caution is advised.

Side effects

Liver failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, fatigue, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous hemorrhage, leukopenia, anemia, rash, itching, photosensitivity reaction, skin-mucosal syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesicular dermatitis, psoriatic rash, psoriasis exacerbation, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, hives, erythema, facial edema, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, mild abdominal pain, diarrhea, discomfort in the stomach, thirst, glossitis, depression, anxiety, headache, taste disturbance, dizziness, drowsiness, sensory abnormalities, sensory reduction, decreased attention, insomnia, elevated BUN, frequent urination, visual disturbances, tinnitus, anaphylactic reactions, angioedema, systemic lupus erythematosus, elevated total cholesterol in the blood, increased triglyceride levels, fatigue, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reactions, serum sickness-like reaction, blurred vision, diminished vision, hearing loss, auditory impairment, vasculitis, permanent loss of smell, anosmia, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine phosphokinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air exposure and preferably kept at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain its efficacy for an extended period.

Appearance and packaging

Appearance

White round tablets

Package unit

30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.